tiprankstipranks
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
US Market
NKTR
Nektar Therapeutics
RESEARCH TOOLSreports

Nektar Therapeutics (NKTR) Stock News & Sentiment

1,602 Followers
Nektar Therapeutics: Buy Rating on Favorable Alopecia Areata Rezpeg Data Outlook and 30‑Day Catalyst Upside Potential
Premium
Ratings
Nektar Therapeutics: Buy Rating on Favorable Alopecia Areata Rezpeg Data Outlook and 30‑Day Catalyst Upside Potential
4d ago
NKTR
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline
Premium
Class Action
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline
8d ago
NKTR
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealed Trial Protocol Violations: Levi & Korsinsky
Premium
Class Action
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealed Trial Protocol Violations: Levi & Korsinsky
16d ago
NKTR
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures
Premium
Class Action
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures
17d ago
NKTR
Nektar Therapeutics: Rezpeg Clinical Momentum and Strong Cash Runway Underscore Attractive Risk‑Reward at Current Levels
Premium
Ratings
Nektar Therapeutics: Rezpeg Clinical Momentum and Strong Cash Runway Underscore Attractive Risk‑Reward at Current Levels
25d ago
NKTR
Buy Rating on Nektar Driven by Rezpeg’s Blockbuster Potential in Atopic Dermatitis and Alopecia Areata
Premium
Ratings
Buy Rating on Nektar Driven by Rezpeg’s Blockbuster Potential in Atopic Dermatitis and Alopecia Areata
25d ago
NKTR
Nektar Therapeutics Bets Big on Respag Phase 3
Premium
Company Announcements
Nektar Therapeutics Bets Big on Respag Phase 3
28d ago
NKTR
More NKTR News >

NKTR News on the Web

Citi opens ‘upside 30-day catalyst watch’ on Nektar into data
TipRanks News
Bullish
Nektar Therapeutics (NKTR) Receives a Buy from Citi
TipRanks News
Bearish
Nektar Therapeutics: Buy Rating on Favorable Alopecia Areata Rezpeg Data Outlook and 30‑Day Catalyst Upside Potential
TipRanks News
Bullish
Nektar Goes Silent: What's Behind The Quiet Period?
rttnews
Neutral
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline
TipRanks News
Bearish
Why Nektar Therapeutics Stock Is Surging Higher Today
TipRanks News
Bullish
Analysts’ Top Healthcare Picks: Insmed (INSM), Nektar Therapeutics (NKTR)
TipRanks News
Neutral

News Score - Last 7 Days

Positive
NKTR
Sector Average
Media Buzz
This Week5 articles
Weekly Average5.5 articles
News Sentiment
This Week75%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is NKTR’s Media Buzz Sentiment?
5 articles about NKTR were published this week. In an average week, 5.5 articles are published.
    What is NKTR’s weekly average amount of articles?
    In an average week, 5.5 articles about NKTR are published.
      What is NKTR’s News Sentiment?
      75% of articles about NKTR were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week